Clinicians may be reluctant to implement evidence-based guideline recommendations because they believe that patients with chronic heart failure (CHF) who are enrolled into clinical trials are not truly representative of those seen in routine practice. Moreover, there may also be perceived safety issues associated with polypharmacy in patients with CHF. Clinicians should strive to implement guideline recommendations for the management of CHF to ensure optimal patient outcome in routine clinical practice.
This case report demonstrates that symptom control may require a large number of pharmacological treatments, to be administered in accordance with guidelines.
McMurray JJV , Östergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet2003; 362:767-71.
2.
Cohn JN, Tognoni G., Valsartan Heart FailureTrial Investigators.A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med2001;345:1667-75.
3.
Swedberg K., Cleland J., Dargie H. et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Taskforce for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology . Eur Heart J2005;26:1115-40.
4.
Maggioni AP, Latini R., Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) . Am Heart J2005;149:548-57.
5.
Swedberg K., Pfeffer M., Cohen-Solal A., Ducharme A.Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartan: results from CHARM. J Am Coll Cardiol2004;43:222A (abstract).
6.
Komajda M., Lapuerta P., Hermans N. et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J2005;26:1653-9.
